Macy's shares are climbing after reporting better-than-expected Q1 adjusted EPS and raising its FY24 outlook. Despite a 2.7% year-on-year sales decline to $4.846 billion, Macy's adjusted EPS of $0.27 beat the $0.15 consensus. The company updated its FY24 sales forecast to $22.3B-$22.9B and adjusted EPS guidance to $2.55-$2.90, reflecting strong customer response to their new strategy.
Lowe's Companies shares rose after reporting better-than-expected Q1 FY24 earnings. Sales declined 4.4% year-on-year to $21.364 billion, surpassing estimates. EPS of $3.06 beat the expected $2.94. Despite a drop in DIY discretionary spending, positive sales in Pro and online sectors helped. Lowe's still projects FY24 revenue of $84-$85 billion and EPS of $12.00-$12.30.
AstraZeneca aims to boost its revenue from $45.8 billion in 2023 to $80 billion by 2030. Key growth drivers include expanding oncology, biopharmaceuticals, rare disease portfolios, and launching 20 new medicines.
Amer Sports is updating guidance for the year ending December 31, 2024 (all guidance figures reference adjusted amounts):
Reported revenue growth: Mid-teens %
Gross margin:
OutlookThe Company is entering the third quarter of fiscal 2024 with approximately $700 million in backlog, which continues to normalize and remain concentrated in systems businesses. Based on current visibility and
Financial Outlook: Zoom is providing the following guidance for its second quarter of fiscal year 2025 and its full fiscal year 2025.Second Quarter Fiscal Year 2025: Total revenue is expected to be between $1.145